Sumitomo Mitsui DS Asset Management Company Ltd Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,863 shares of the company’s stock after buying an additional 657 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Moderna were worth $1,450,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. AQR Capital Management LLC increased its holdings in Moderna by 32.0% during the 2nd quarter. AQR Capital Management LLC now owns 5,083 shares of the company’s stock worth $604,000 after acquiring an additional 1,232 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Moderna by 278.2% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,772 shares of the company’s stock valued at $185,000 after purchasing an additional 2,039 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Moderna by 164.0% in the third quarter. Exchange Traded Concepts LLC now owns 17,558 shares of the company’s stock worth $1,173,000 after purchasing an additional 10,907 shares during the period. Swedbank AB raised its position in shares of Moderna by 149.6% in the third quarter. Swedbank AB now owns 85,099 shares of the company’s stock worth $5,687,000 after buying an additional 51,000 shares in the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after buying an additional 69,313 shares during the period. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. UBS Group decreased their target price on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Morgan Stanley lowered their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Finally, Berenberg Bank lifted their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $66.89.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last three months. 15.20% of the stock is owned by company insiders.

Moderna Stock Performance

Shares of MRNA stock opened at $30.93 on Wednesday. The company has a market capitalization of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59. Moderna, Inc. has a fifty-two week low of $30.70 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock has a 50 day moving average price of $39.77 and a two-hundred day moving average price of $56.76.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.